Biotech Investment Dynamics
Chamath highlights the interconnectedness of public and private biotech funding, suggesting that regulatory changes could shift investor risk appetites. He commends recent actions against pharmacy benefit managers as a more effective approach to tackling drug price inflation, contrasting it with the ongoing scrutiny of mergers. The discussion also touches on the evolving landscape of speculative acquisitions in the biotech sector.In this clip
From this podcast
All-In Podcast
E129: Sam Altman plays chess with regulators, AI's "nuclear" potential, big pharma bundling & more
Related Questions